Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Completes Repurchase of $92M of Senior Notes as Part of Settlement

NEW YORK (GenomeWeb News) – Affymetrix said in a regulatory filing that it has repurchased almost $92 million of senior convertible notes related to a settlement of a lawsuit associated with its proposed purchase of eBioscience.

In a document filed with the US Securities and Exchange Commission Tuesday, the company said that as of the expiration date of its offer to repurchase the notes at midnight on March 2, $91.6 million in aggregate principal of the notes, or 96 percent of the outstanding notes, had been validly tendered and not withdrawn.

The company settled the offer on March 5 and paid its holders aggregate consideration of $92.1 million, including the accrued interest.

Affy had commenced a tender offer in early February to repurchase the entire $95.5 million in aggregate principal amount of its 3.50 percent senior convertible notes due 2038 as part of settlement with Tang Capital, which had sued Affy following its announcement to buy eBioscience for $330 million.

Tang claimed the acquisition would constitute a fundamental change under the indenture that governs the senior convertible notes that it held.

Affy disclosed in its Form 10-K last week that it has released eBioscience from certain obligations under the terms of its merger deal. eBioscience is considering alternatives to an acquisition by Affy, it added.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.